Drug
Cintredekin besudotox clinical trials
Also written IL13-PE38QQR.
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2000
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2001 (2)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2009 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
INSYS Therapeutics Inc (8) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Pediatric Brain Tumor Consortium (1)
Often tested with
Tested in the same studies.
Carmustine, poliferprosan 20 drug combination (1)
Studies
Open first, then newest update. How each study uses cintredekin besudotox is read from its arms, and is right about nine times in ten.
Testing it · 11
- An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade GliomaTerminatedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT00880061Written as IL13-PE38QQR
- Possible New Therapy for Advanced CancerTerminatedPhase 1INSYS Therapeutics IncNCT01832974Written as IL-13-PE
- Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant GliomaCompletedPhase 1/2INSYS Therapeutics IncNCT00024570Written as IL13-PE38QQR
- Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant GliomaWithdrawnPhase 1/2INSYS Therapeutics IncNCT00378235Written as IL13-PE38QQR
- Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant GliomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00036972Written as cintredekin besudotox
- IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant GliomaCompletedPhase 1INSYS Therapeutics IncNCT00089427Written as IL13-PE38QQR
- Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma PatientsCompletedPhase 1INSYS Therapeutics IncNCT00024557Written as IL13-PE38QQR
- The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedPhase 3INSYS Therapeutics IncNCT00076986Written as IL13-PE38QQR
- Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant GliomaCompletedPhase 1INSYS Therapeutics IncNCT00064779Written as IL13-PE38QQR
- Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedPhase 1/2INSYS Therapeutics IncNCT00041587Written as IL13-PE38QQR
- Immunotoxin Therapy in Treating Children With Recurrent Malignant GliomasWithdrawnPhase 1/2Pediatric Brain Tumor ConsortiumNCT00053040Written as cintredekin besudotox
Codes
What other systems call cintredekin besudotox · ClinicalTrials.gg INT005129
- UNII (FDA) ZL04JX89M7CINTREDEKIN BESUDOTOXConfirmed FDA, NLM
- NCI Thesaurus C2599Cintredekin BesudotoxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZL04JX89M7 | CINTREDEKIN BESUDOTOX | Confirmed FDA, NLM |
| NCI Thesaurus | C2599 | Cintredekin Besudotox | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.